Obstacles to the Development of a Neuroprotective Therapy for Parkinson's Disease
Published 2013 View Full Article
- Home
- Publications
- Publication Search
- Publication Details
Title
Obstacles to the Development of a Neuroprotective Therapy for Parkinson's Disease
Authors
Keywords
-
Journal
MOVEMENT DISORDERS
Volume 28, Issue 1, Pages 3-7
Publisher
Wiley
Online
2013-02-07
DOI
10.1002/mds.25337
References
Ask authors/readers for more resources
Related references
Note: Only part of the references are listed.- Overcoming obstacles in Parkinson's disease
- (2012) Todd B. Sherer et al. MOVEMENT DISORDERS
- Design innovations and baseline findings in a long-term Parkinson's trial: The national institute of neurological disorders and stroke exploratory trials in Parkinson's Disease Long-Term Study-1
- (2012) Jordan J. Elm et al. MOVEMENT DISORDERS
- Pathogenesis of Parkinson's disease
- (2012) Etienne C. Hirsch et al. MOVEMENT DISORDERS
- Animal models of Parkinson's disease: Limits and relevance to neuroprotection studies
- (2012) Erwan Bezard et al. MOVEMENT DISORDERS
- Leucine-rich repeat kinase 2 (LRRK2) as a potential therapeutic target in Parkinson's disease
- (2012) Byoung Dae Lee et al. TRENDS IN PHARMACOLOGICAL SCIENCES
- Recent Advances in the Genetics of Parkinson's Disease
- (2011) Ian Martin et al. Annual Review of Genomics and Human Genetics
- A double-blind, delayed-start trial of rasagiline in Parkinson's disease (the ADAGIO study): prespecified and post-hoc analyses of the need for additional therapies, changes in UPDRS scores, and non-motor outcomes
- (2011) Olivier Rascol et al. LANCET NEUROLOGY
- Milestones in PD genetics
- (2011) Thomas Gasser et al. MOVEMENT DISORDERS
- The Parkinson Progression Marker Initiative (PPMI)
- (2011) Kenneth Marek et al. PROGRESS IN NEUROBIOLOGY
- An introduction to adaptive designs and adaptation in CNS trials
- (2010) Vladimir Dragalin EUROPEAN NEUROPSYCHOPHARMACOLOGY
- Parkinson's at risk syndrome: Can Parkinson's disease be predicted?
- (2010) Matthew B. Stern et al. MOVEMENT DISORDERS
- Defining disease-modifying therapies for PD-A road map for moving forward
- (2010) C. Warren Olanow et al. MOVEMENT DISORDERS
- Bioactivity of AAV2-neurturin gene therapy (CERE-120): Differences between Parkinson's disease and nonhuman primate brains
- (2010) Raymond T. Bartus et al. MOVEMENT DISORDERS
- Genetic Animal Models of Parkinson's Disease
- (2010) Ted M. Dawson et al. NEURON
- Endpoints and Analyses to Discern Disease-Modifying Drug Effects in Early Parkinson’s Disease
- (2009) Venkatesh Atul Bhattaram et al. AAPS Journal
- Modeling Parkinson's disease
- (2009) C. Warren Olanow et al. ANNALS OF NEUROLOGY
- A Double-Blind, Delayed-Start Trial of Rasagiline in Parkinson's Disease
- (2009) C. Warren Olanow et al. NEW ENGLAND JOURNAL OF MEDICINE
- Is Parkinson's disease a prion disorder?
- (2009) C. W. Olanow et al. PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA
- A randomized, double-blind, placebo-controlled, delayed start study to assess rasagiline as a disease modifying therapy in Parkinson's disease (the ADAGIO study): Rationale, design, and baseline characteristics
- (2008) C. Warren Olanow et al. MOVEMENT DISORDERS
- Movement Disorder Society-sponsored revision of the Unified Parkinson's Disease Rating Scale (MDS-UPDRS): Scale presentation and clinimetric testing results
- (2008) Christopher G. Goetz et al. MOVEMENT DISORDERS
Find Funding. Review Successful Grants.
Explore over 25,000 new funding opportunities and over 6,000,000 successful grants.
ExploreBecome a Peeref-certified reviewer
The Peeref Institute provides free reviewer training that teaches the core competencies of the academic peer review process.
Get Started